Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 3Completed 3Unknown 2Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 133Breast 67Tumor-Agnostic 9Head & Neck 6CNS 6Thoracic 5Gynecologic 5Genitourinary 5Endocrine 4Dermatologic 3Other solid neoplasm 2NET 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Neuroendocrine Tumors 1Neoplasms 1Gastro-entero-pancreatic Neuroendocrine Tumors 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 3lanreotide 3Erlotinib Hydrochloride 3surufatinib 2gallium Ga 68 dotatate 2dactolisib 2Sunitinib 2Octreotide 2Magnetic Resonance Spectroscopy 2Filgrastim 2Capecitabine 2trifluridine tipiracil drug combination 1tislelizumab 1telotristat ethyl 1telotristat 1pertuzumab 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1fosbretabulin 1folfirinox 1famitinib 1entinostat 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1alectinib 1Temozolomide 1Surveys and Questionnaires 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Capecitabine × NET × Clear all
NCT07012330 2025-06-10

Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients

Erasmus Medical Center

Phase 2 Terminated
111 enrolled
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT02736448 2025-01-13

Lu-Ca-S

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
35 enrolled
EndocrineGastrointestinalNET

Gastro-entero-pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡